AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

A Phase 1, Single-center, Randomized, Open-label, Two-way Crossover, Formulation and Food Effect Study in Healthy Volunteers, to Assess the Pharmacokinetics of AZD 2066 After Single Doses of a New Oral Solid Formulation and an Oral Solution

A open label two way crossover formulation and food effect study in healthy volunteers to assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an oral solution

Inclusion Criteria:

• Clinical normal physical findings, including BP, pulse rate >45 bpm, ECG and laboratory assessments
• Body Mass Index (BMI) of ≥18 to ≤30 kg/m2 and weight of ≥50 to ≤100 kg

Exclusion Criteria:

• History of hypersensitivity, allergy or atopic/skin disease as judged by Investigator.
• History of somatic or psychiatric disease/condition, which may interfere with the objectives of the study as judged by the Investigator.